Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Gala Global Inc. Subsidiary Controlled Environment Genomics Inc. Files Provisional Patent Application on State-of-the-Art Fully Automated Computer Controlled Genetically Modified Plant Cloning Technology

Posted on: 08 Aug 17

AKRON, Ohio, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Controlled Environment Genomics Inc. (CEG), a subsidiary of Gala Global, Inc. (OTC:GLAG), today announced that it has successfully filed a provisional patent application on its proprietary, fully automated, computer-controlled, genetically modified plant cloning technology through the company’s IP legal counsel, Los Angeles-based Tucker Ellis LLP.

Under U.S. patent law, the provisional application is a legal document which is filed in the U.S. Patent and Trademark Office (USPTO) to establish an early filing date. The application will mature into an issued patent when CEG files a regular non-provisional patent application within one year.

CEG is a start-up biotechnology company focused on the development and commercialization of computer-controlled digital plant cloning incubators for use in the agricultural and biopharmaceutical industries. 

Gala Global Inc. is a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotech industry. It targets investments in companies commercializing biotechnologies, including indoor agriculture, molecular biology, genetics and biopharmaceutical compounds. 

“We are excited to have completed this first major milestone in the development of our turnkey digital plant cloning incubation systems,” said Gala Global CEO Timothy Madden. “The next major accomplishment in the very near future will be the completion of the first commercial-use system in the research laboratory at the University of Akron’s Department of Biomedical Engineering.”

CEG is also collaborating with technology partner GenoBreeding Inc., Anaheim, Calif., on developing breeding tools such as molecular markers to enable productive plant breeding decisions and processes that achieve top-tier plant performance in a sustainable manner.

CEG’s state-of-the-art genomics technology enables GenoBreeding to digitally sequence the genomes of the most desirable plant varieties based on flavor and nutrition. Desirable traits can then be used to improve the most desirable commercial varieties with traits like increased yield and quality, thus enhancing consumer demand for the product and increasing the company’s profitability.

GenoBreeding is also developing a proprietary digital genetic database that will be used as an online cloud-based library of digitally sequenced genomes and phenotypic (chemical composition) information on all existing and new plant varieties. 

CEG’s proprietary digital plant cloning technology will enable GenoBreeding geneticists to select the best plant varieties to hybridize with the aim of improving and increasing crop quality and yields by combining the very best genetics to maximize the variation of positive inherited characteristics in each variety.

About Controlled Environment Genomics Inc.

Controlled Environment Genomics, Inc. (CEG), Akron, Ohio, is a genomics company with expertise in digital plant gene sequencing, editing and cloning technologies. CEG is a subsidiary of Gala Global Inc., Anaheim, Calif., a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotechnology industry. CEG’s state-of-the-art genomics technology enables computerized genome sequencing and plant cloning using a fully automated turnkey solution for digitally sequencing the genomes of the world’s most desirable plant varieties based on flavor and nutrition. CEG improves the most valuable crop varieties currently available on the market by utilizing proprietary Cloud computing-based digital cloning technologies to crossbreed crops that have advantageous traits with established varieties featuring the best genetic profiles for commercial production. The very best plant traits can be used to improve the most sought-after commercial varieties by adding characteristics like maximized yields and quality conducive to increased consumer demand and optimized production profitability.

About GenoBreeding Inc.

GenoBreeding Inc., a subsidiary of Greengro Technologies, Inc. (OTC:GRNH), Anaheim, Calif., was formed in early 2017 to direct a Greengro initiative intended to bring to the cannabis market cutting-edge plant varieties through the application of modern plant breeding technologies conducive to increased consumer demand and improved production profitability.

About Gala Global Inc.

Gala Global, Inc. (OTC:GLAG), a publicly-traded research and development company that specializes in equity investments, debt financing and mergers and acquisitions (M&A) in the biotech industry. Gala Global’s professional services group provides operational services and technologies that drive efficiencies in the market. Gala Global has industry-leading expertise helping companies make the most of their potential in an emerging market. Gala Global website:

Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.

CONTACT: Investor/Media Contact:                    Christopher Persaud                             Investor Relations Partners                                                     Phone:  844-565-5665GlobeNewswire

Last updated on: 08/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.